key: cord-0685112-un0qxap5
authors: Kouwaki, Takahisa; Nishimura, Tasuku; Wang, Guanming; Nakagawa, Reiko; Oshiumi, Hiroyuki
title: Ubiquitin ligase RIPLET mediates polyubiquitination of RIG-I and LGP2 and regulates the innate immune responses to SARS-CoV-2 infection
date: 2021-01-28
journal: bioRxiv
DOI: 10.1101/2021.01.25.428042
sha: 975142f554d42aae37fba2a7856ed38295a48cfc
doc_id: 685112
cord_uid: un0qxap5

RIG-I, a cytoplasmic viral RNA sensor, is crucial for innate antiviral immune responses; however, there are controversies about RIG-I’s regulatory mechanism by several ubiquitin ligases and LGP2. Our genetic study revealed that the RIPLET ubiquitin ligase was a general activating factor for RIG-I signaling, whereas another ubiquitin ligase, TRIM25, activated RIG-I in a cell-type-specific manner. These RIPLET and TRIM25 functions were modulated by accessory factors, such as ZCCH3C and NLRP12. Interestingly, we found an additional role of RIPLET in innate immune responses. RIPLET induced delayed polyubiquitination of LGP, resulting in the attenuation of excessive cytokine expression at the late phase. Moreover, RIPLET was involved in the innate immune responses against SARS-CoV-2 infection, a cause of the recent COVID-19 pandemic. Our data indicate that RIPLET fine-tunes innate immune responses via polyubiquitination of RIG-I and LGP2 against virus infection, including SARS-CoV-2.

Cytoplasmic viral RNA sensing initiates innate antiviral immune responses, including type I interferon (IFN) production. RIG-I is a member of the RIG-I-like receptors (RLRs) and senses 5´ tri-and di-phosphate viral double-stranded RNA (dsRNA) 1 Although RIG-I is crucial for innate antiviral immune responses, excessive RIG-I activation leads to autoimmune disorders 6 . Thus, RIG-I should be tightly controlled by several RIG-I regulators.

The RIG-I protein comprises two caspase activation and recruitment domains (2CARDs), RNA helicase domain, and C-terminal domain (CTD). The protein harbors post-translational modifications, and it has been shown that K63-linked polyubiquitin chains are essential for RIG-I activation 7 . TRIM25 is an E3 ubiquitin ligase that delivers the K63-linked polyubiquitin moiety to RIG-I 2CARDs 7 . The polyubiquitin chains stabilize the 2CARD tetramer structure and promote type I IFN expression 8 . Recent studies have identified several TRIM25 regulators. The ZCCHC3 and NDR2 proteins promote TRIM25-mediated activation of RIG-I, thereby enhancing innate antiviral immune responses 9, 10 . In contrast, NLRP12 inhibits TRIM25 to attenuate RIG-I-mediated signaling 11 .

RIPLET is another ubiquitin ligase that mediates K63-linked polyubiquitination of the CTD and CARDs, and is essential for RIG-I activation 12, 13, 14, 15 . Although many groups have reported TRIM25 as essential for RIG-I activation 1 , several recent studies have challenged this model and shown that RIPLET, but not TRIM25, is necessary for RIG-Imediated innate immune responses 14, 16, 17 . Besides these contradictions, the ubiquitin ligases MEX3C and TRIM4 have been reported to mediate K63-linked polyubiquitination of RIG-I CARDs 18, 19 . These apparent contradictions are still unresolved 1, 20, 21 .

LGP2 and MDA5 are other RLRs involved in innate antiviral immune responses, including type I IFN expression 22 . LGP2 was once reported as a negative regulator because its over-expression attenuates RIG-I-mediated type I IFN expression 23 . However,

LGP2 knockout (KO) exhibited a defect in RIG-I-mediated type I IFN expression after viral infection 24 .

LGP2 regulates MDA5 assembly on viral RNA 25 . It has recently been shown that an E3 ubiquitin ligase binds to LGP2 26 ; however, the role of LGP2 polyubiquitination in RIG-I activation remains unclear.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a virus causing coronavirus disease 2019 27 . The viral spike protein binds to human angiotensin-converting enzyme 2 (ACE2) to infect host cells 27 . The cytoplasmic innate immune response against SARS-CoV-2 remains unclear. Since several viruses have evolved to escape the host innate immune response 1 , it is expected that SARS-CoV-2 can also suppress the innate immune response.

Here, we focused on the role of RIPLET in RIG-I-mediated cytoplasmic antiviral innate immune response. Our genetic data showed that RIPLET is a general activating factor for RIG-I. In contrast, TRIM25 KO exhibited a defect in RIG-I activation in a celltype-specific manner. We also found RIPLET-mediated polyubiquitination of LGP2. Defective RIG-I-mediated type I IFN expression was also detected in RIPLET KO HeLa cells (Fig. 1l) . Still, there was no defect in type I IFN expression in TRIM25-KO HeLa cells (Fig. 1i) , suggesting that the observation of no defect of RIG-I signaling in TRIM25-KO cells was not specific to HEK293 cells. The DKO of TRIM25 and RIPLET also exhibited a severe defect in short poly I:C-induced expression of IFN-β, IP-10, and Ccl5 mRNA ( Fig. 1j and Supplementary Figs. S2a-c).

Next, we observed the subcellular localization of RIPLET, TRIM25, RIG-I, and K63linked polyubiquitin chains. Proximity ligation assay (PLA) was used to detect the co-localization of two proteins, and the number of endogenous RIG-I and Riplet colocalization PLA signals was increased after stimulation with short poly I:C (Figs. 1k and l), which was consistent with the observation that RIPLET binds to RIG-I after stimulation 12 . Interestingly, several PLA signals were detected on rhodamine-conjugated short poly I:C and mitochondria (Supplementary Figs. S2d and e). Co-localization of RIG-I and K63-linked polyubiquitin chains were also detected by PLA (Fig. 1m) . The number of PLA signals was markedly increased after stimulation with short poly I:C, and RIPLET KO abolished the signals (Figs. 1m and n). Several PLA signals were localized on rhodamine-conjugated short poly I:C; however, there were many signals that were not co-localized with the short poly I:C (Supplemental Fig. S2f ), implying that ubiquitinassociated RIG-I detached from the ligands after its activation. Our data collectively indicate that the RIPlET, but not TRIM25, MEX3C, nor TRIM4, is essential for RIG-I activation in several cell types, and this notion is consistent with a previous report by Cadena C et al. 14 .

Although TRIM25 KO unaffected RIG-I-dependent type I IFN expression in HEK293

and HeLa cells, we found that TRIM25 KO reduced IFN-β mRNA expression in A549 cells at the early phase after stimulation with short poly I:C (Fig. 2a) , and IP-10 and Ccl5 expression was also reduced by TRIM25 KO at both the early and late phases (Figs. 2b and c). Notably, RIPLET KO also abolished the cytokine expression in response to a RIG-I ligand even in A549 cells . TRIM25 KO failed to reduce IFN-β mRNA expression after SeV infection (Fig. 2d) . In contrast, it moderately reduced IP-10 and Ccl5 mRNA expression in response to SeV infection (Figs. 2e and 2f). To further test the defect of TRIM25 KO in RIG-I activation, we sought to generate additional TRIM25 KO cells and obtained two A549 TRIM25 KO clones (clone #2 and #9). We found that TRIM25 KO significantly reduced the expression of IP-10 and Ccl5 mRNA in two independently isolated TRIM25 KO clones in response to short poly I:C stimulation (Figs. 2g-i), and IP-10 and Ccl5 mRNA expression induced by SeV infection was also reduced in a TRIM25 KO clones (Fig. 2j) . Additionally, Ccl5 mRNA expression was reduced by TRIM25 KO in SKOV3 cells after SeV infection (Fig. 2k ). PLA signals of endogenous RIG-I and TRIM25 were detected on short poly I:C as was the case with those of RIG-I and Riplet (Fig. 2l ). Considering these data, we prefer the interpretation that TRIM25 activates RIG-I in a cell-type-specific manner (see discussion).

Since recent studies have reported several proteins that regulate TRIM25-mediated RIG-I activation 9, 10, 11 , we hypothesized that the expression of these factors might be required for TRIM25 to activate RIG-I. It has been shown that ZCCHC3 promotes TRIM25-mediated RIG-I activation 10 . ZCCHC3 KO moderately reduced RIG-I-mediated IFN-β and Ccl5 mRNA expression (Supplementary Figs. S2g-i). Although TRIM25 KO did not show any defect in RIG-I signaling in HEK293 cells as described above, TRIM25 KO reduced RIG-I-induced IFN-β promoter activities in ZCCHC3-overexpressing cells (Fig. 2m) . We confirmed that RIPLET over-expression enhanced ZCCHC3-mediated RIG-I activation ( Supplementary Fig. S2j ) and that RIPLET KO abolished RIG-Imediated type I IFN promoter activation, even in ZCCHC3-overexpressing cells (Fig. 2n) .

These observations are consistent with the notion that ZCCHC3 promotes TRIM25mediated RIG-I activation.

NDR2 and NLRP12 have been reported to modulate TRIM25-mediated RIG-I activation 9, 11 . However, NDR2 over-expression augmented RIG-I-mediated IFN-β promoter activation not only in wild-type cells but also in TRIM25 KO cells (Fig. 3a) .

Also, NLRP12 over-expression reduced RIG-I-mediated signaling in WT and TRIM25 KO cells ( Fig. 3b and 3c) . These data suggest that NDR2 and NLRP12 regulate RIG-I activities in TRIM25-dependent and -independent manners. Thus, we next investigated the physical interactions between these factors and RIPLET.

Our immunoprecipitation assay showed that RIPLET was co-immunoprecipitated with NLRP12 ( Fig. 3d) , and NLRP12 expression reduced the physical interaction between RIG-I and RIPLET (Fig. 3e) . TRIM25 binds to the nucleotide-binding domain (NBD) of NLRP12 11 . Our immunoprecipitation assay with truncated forms of NLRP12 showed that RIPLET bound to the pyrin domain of NLRP12, and the NBD inhibited the interaction ( Fig. 3f) . Moreover, NLRP12 expression inhibited RIPLET-mediated RIG-I polyubiquitination of RIG-I (Fig. 3g) . These data suggest that the accessory factors are involved in both RIPLET-and TRIM25-mediated RIG-I activations.

Next, we focused on the role of LGP2, because unknown function of LGP2 may underlie the controversy.

LGP2 is a member of the RLRs. Its over-expression reduced RIG-I- Since there are similarities between the CTDs of RIG-I and LGP2 28 , we investigated the physical interaction between RIPLET and LGP2 and found that the RIPLET protein was co-immunoprecipitated with LGP2 (Figs 4e and f). Additionally, PLA signals of RIPLET-HA and FLAG-LGP2 were detected (Fig. 4g) . Interestingly,

LGP2 harbored polyubiquitin modifications, and RIPLET enhanced LGP2 polyubiquitination (Fig. 4h ). To investigate whether the modification was K63-linked polyubiquitination, K63-only ubiquitin, in which all K residues of ubiquitin except K at 63 were replaced with R, was utilized to detect LGP2 ubiquitination. K63-only ubiquitin was efficiently incorporated into LGP2, and that the polyubiquitin bands were increased by RIPLET expression (Fig. 4i) . Conversely, RIPLET KO reduced the polyubiquitination of LGP2 (Fig. 4j) . The PLA signals of endogenous LGP2 and K63-polyubiquitin were observed. The number of signals was increased by stimulation with short poly I:C, and RIPLET KO abolished the PLA signals (Fig. 4k) . Additionally, the signals were detected on transfected rhodamine-short poly I:C (Fig. 4l) . These data suggested that RIPLET mediated K63-linked polyubiquitination of LGP2.

Since the immunoprecipitation assay and PLA suggested that RIPLET ubiquitinated

LGP2, we performed a mass spectrometry analysis to determine the ubiquitination sites of LGP2. We found that K39, K532, K599, and K629 of LGP2 were ubiquitinated in RIPLET-expressing cells ( Fig. 5a and Supplementary Fig. S3c ). The alignment of LGP2 and RIG-I showed that K532 and K599 of LGP2 were comparable with K788 and K851 of RIG-I, which are ubiquitinated by RIPLET ( Supplementary Fig. S3d ).

Immunoprecipitation assay showed that RIPLET preferentially bound to the helicase domain of LGP2, although the CTD is also associated with RIPLET (Fig. 5b) , which is consistent with a recent study showing that ubiquitin ligases bind to the helicase domain of RLRs 26 . The 3KR amino acid substitutions within the CTD reduced the polyubiquitination of LGP2 CTD (Fig. 5c ), but residual polyubiquitination was still detected.

To investigate the physiological significance of LGP2 polyubiquitination, we constructed a LGP2-4KR mutant in which K39, K532, K599, and K629 of LGP2 were replaced with the R residue. Both non-ubiquitinated and polyubiquitinated wild-type and

LGP2-4KR mutant proteins were recovered by pull-down assay with poly I:C-conjugated streptavidin beads (Fig. 5d) , suggesting that polyubiquitination did not affect the RNAbinding activity of LGP2. To investigate the effect of LGP2 ubiquitination on cytokine expression, we constructed LGP2 KR mutants. We observed a moderate increase in RIG-I-mediated IFN-β promoter activation with the K39R or K532R substitution, and the K629R mutation significantly increased the promoter activities ( Fig. 5e ). We generated cells that stably expressed wild-type LGP2 or LGP2-4KR using a lentivirus vector 29 .

Stable expression of wild-type or mutant LGP2 unaffected the IFN-β promoter activities in non-stimulated cells (Fig. 5f) . Interestingly, the LGP2-4KR mutant protein induced the promoter activity more than the wild-type protein in response to a RIG-I ligand (Fig. 5f ).

These data suggested that LGP2 ubiquitination negatively affects type I IFN expression. 

Studies have shown that RIPLET plays a crucial role in the innate immune response to viral infection, such as influenza A, vesicular stomatitis virus, Sendai, and hepatitis C virus 12, 32 . Since SARS-CoV-2 is a virus causing the COVID-19 pandemic, we investigated whether RIPLET is involved in the innate immune response to SARS-CoV-2. First, we investigated whether RIG-I recognizes SARS-CoV-2 RNA.

VeroE6/TMPRSS2 cells were infected with SARS-CoV-2, and the total RNA of infected cells was extracted. Extracted RNAs from infected and non-infected cells were transfected into HEK293 cells, and cytokine expression was measured. Total RNAs from virus-infected cells but not those from uninfected cells induced cytokine expression ( We confirmed that SARS-CoV-2 replicated in HEK293 cells (Fig. 7j) . Recent studies have shown that viral proteins of SARS-CoV-2 can suppress the innate immune responses, and we also found that several viral proteins suppressed the RIG-I-mediated IFN-β promoter activation ( Supplementary Fig. S4f ). To further address the role of RIPLET in the innate immune response, we generated human ACE2 overexpressing HEK293 cells (HEK293-ACE2) to increase the infectivity of SARS-CoV-2 to HEK293 cells as previously reported 27, 35 . In HEK293-ACE2 cells, SARS-CoV-2 infection induced moderate expression of type I IFN expression, and RIPLET KO reduced the cytokine expression ( Supplementary Fig. S4g ). Interestingly, RIPLET KO significantly increased the cytoplasmic viral levels after SARS-CoV-2 infection (Fig. 7k ). Our data collectively indicate that RIPLET is required for the antiviral innate immune response against SARS-CoV-2.

RIG-I is a cytoplasmic viral RNA sensor that is essential for innate antiviral immune responses. Although there is controversy about RIG-I regulators, our data revealed that RIPLET ubiquitin ligase is a general factor for RIG-I activation, and TRIM25 KO exhibited a defect in RIG-I activation in a cell-type-specific manner. Moreover, several accessory factors affected not only TRIM25-but also RIPLET-mediated RIG-I activation.

We also found that RIPLET induced delayed polyubiquitination of LGP2, which attenuates the excessive cytokine expression. Furthermore, RIPLET was essential for the antiviral innate immune response against SARS-CoV-2, which is a cause of the recent COVID-19 pandemic. These data elucidated a crucial role of the RIPLET ubiquitin ligase in regulating antiviral innate immune responses.

K63-linked polyubiquitination of RIG-I is an essential step to trigger the expression of type I IFN and other pro-inflammatory cytokines. Many studies have reported that TRIM25 delivers the K63-linked polyubiquitin moiety to RIG-I, thereby inducing type I IFN expression in vitro and in vivo 1 . However, recent studies have challenged this model 14, 16, 17 . Here, we carefully assessed the ubiquitin ligases' role using single-, double-, and triple-KO cells and the obtained data that reconciled the apparent discrepancy. As reported by Cadena et al., we found that RIPLET KO severely reduced RIG-I-dependent cytokine expression in any cell type as far as we tested. In contrast, TRIM25 KO attenuated the RIG-I-dependent cytokine expression only in a cell-type-specific manner.

Considering that TRIM25 has been considered essential for RIG-I activation in any cell types 7 , our finding would reconcile previous apparent discrepancy of why TRIM25 KO exhibited a defect in RIG-I activation in some studies but did not in other studies 1, 21 .

In addition to RIPLET and TRIM25, MEX3C and TRIM4 were reported to be involved in RIG-I ubiquitination. Unlike TRIM25 and RIPLET, we could not see any effect of MEX3C KO or TRIM4 KO on RIG-I activation at least in our experimental conditions. We do not exclude the possibility that MEX3C and TRIM4 might be required for RIG-I activation in a cell-type-specific manner, as seen with TRIM25. Recent studies have reported several factors that regulate TRIM25 functions. Since TRIM25 decreased RIG-I-mediated type I IFN expression in HEK293 cells expressing ZCCHC3; it is expected that some types of immortalized cells lack the factors' expression required for TRIM25mediated RIG-I activation.

Some of TRIM25 KO, MEX3C KO, and/or TRIM4 KO exhibited enhanced cytokine expression in response to RIG-I stimulation in our experimental conditions. These observations were also observed in a previous study by Cadena et al 14 . Thus, it is suspected that some suppressor mutations occurred on other unknown genes during the isolation of those KO cells. Considering that ubiquitin ligases target several proteins, it is not surprising that suppressor mutations occur in ubiquitin ligase KO cells 36, 37 . Those spontaneous suppressor mutations might affect the phenotypes of TRIM25 KO cells.

Thus, we prefer the interpretation that TRIM25 activates RIG-I in a cell-type-specific manner rather than the model that TRIM25 is not involved in RIG-I activation. Further studies using TRIM25 KO mice and TRIM25 KO primary cells are required to settle the dispute.

The decrease in of IP-10 and Ccl5 expression was more significant than that of IFN-β in TRIM25 KO cells. The MAVS adaptor induces cytokine expression via mitochondria or peroxisome 38 . Peroxisomal MAVS preferentially activates the transcription of interferon-stimulated genes including IP-10, using IRF1 and IRF3, whereas mitochondrial MAVS activates only IRF3, thereby inducing type I IFN expression 38 .

Considering that TRIM25 KO exhibited more severe defects in IP-10 and Ccl5 expression than that of type I IFN, it is possible that TRIM25-mediated polyubiquitin chain preferentially activates peroxisomal MAVS. Since RIPLET functions as a co-receptor for RIG-I and an E3 ubiquitin ligase for RIG-I, it is still possible that K63-linked polyubiquitin chains are important for RIG-I-induced IP-10 and Ccl5 expression, and the co-receptor function of RIPLET is required for the type I IFN expression. This is also supported by the notion that the mutations on the ubiquitinated RIG-I residues exhibited a relatively moderate phenotype compared with RIPLET KO. Further studies are required to address this issue.

Abnormal activation of RIG-I causes Singleton-Merten syndrome, which is a multisystem autoimmune disorder, and an excessive innate immune response is harmful to the host 6 . We identified an additional role of RIPLET: it mediated K63-linked polyubiquitination of LGP2, leading to the attenuation of excessive type I IFN expression at the late phase.

LGP2 was once reported as a negative regulator 22, 23 , but later studies have shown that LGP2 plays a positive role in RIG-I-mediated cytokine expression 24 .

This study showed that LGP2 KO reduced RIG-I-mediated cytokine expression, but inhibition of LGP2 ubiquitination enhanced cytokine expression. These observations indicate that LGP2 has a dual role in the regulation of RIG-I signaling. This model can explain why ectopically expressed LGP2 exhibits a negative effect because LGP2 overexpression led to LGP2 polyubiquitination that attenuated RIG-I signaling. K63-linked polyubiquitination of LGP2 was detected only at the late phase after stimulation of RIG-I. Thus, delayed polyubiquitination of LGP2 is expected to be a negative feedback mechanism to suppress excessive cytokine expression harmful to the host.

Cytokine storm is suspected to be a cause of mortality in patients with COVID-19 30 .

Indeed, treatment with tocilizumab, a monoclonal antibody against IL-6, reduces the mortality of patients with COVID-19 39 . Therefore, we prefer the interpretation that both RIPLET-dependent RIG-I and LGP2 ubiquitination would be essential to protect the host from viral infection. Since SARS-CoV-2 infection hardly induced type I IFN and proinflammatory cytokine expression in HEK293 and HEK293-ACE2 cells, RIPLETdependent cytoplasmic innate immune system seems to be uninvolved in harmful excessive pro-inflammatory cytokine production in patients with COVID-19. Toll-like receptors, such as TLR3, TLR7, and TLR8, might be involved in excessive proinflammatory cytokine production. We do not exclude the possibility that some kinds of cells produce pro-inflammatory cytokine via RIPLET-dependent cytoplasmic innate immune response during SARS-CoV-2 infection. However, our observation that several viral proteins can suppress the cytoplasmic innate immune response weakens this possibility.

Although there are several contradictory reports related to RIG-I ubiquitination and the role of LGP2 in innate immune response, our data could reconcile those apparent discrepancies as discussed above. The molecular mechanism of RIPLET-dependent regulation of RIG-I and LGP2 would be required to fully understand the intracellular innate immune responses against viral infections including SARS-CoV-2.

We thank our laboratory members for helpful discussion. This work was supported in part by Grants-in-Aid from the Ministry of Education, Culture, Sports, Science, and 

The authors declare no competing interests. (c-f) The viral RNA segment (24001-25000) was transfected into WT, RIG-I KO, MDA5

KO, and Riplet KO cells. Total RNA was extracted at indicated time points, and the expression of the cytokines were determined by RT-qPCR. The data represents the mean ± SD (n = 3, *p < 0.05, t-test).

(g-j) HEK293 were infected with influenza A virus (g), SeV (h), and SARS-CoV-2 (i, j)

at MOI = 1. Total RNA was extracted at indicated time points, and the cytokine mRNA and viral RNA were determined by RT-qPCR. The data represents the mean ± SD (n = 3).

(k) HEK293 cells stably expressing ACE2 were infected with SARS-CoV-2 at indicated MOI for 18 hr. IFN-β mRNA, IP-10 mRNA, and negative stranded viral RNA of SARS-CoV-2 were determined by RT-qPCR. The data represents the mean ± SD (n = 3, *p<0.05, t-test).

TRIM4-, TRIM25-, MEX3C-, Riplet-, ZCCHC3-, and LGP2-KO cells were generated using a CRISPR/Cas9 system. The guide sequence (See Table S1 ) was cloned into a BbsI LGP2 KR mutants were amplified using two fragments as templates and cloned into the pEF-BOS-FLAG vector. CoV-2 was isolated with TRIZOL, and cDNA was prepared using random primer. The cDNA fragments encoding the viral RNA segments were amplified with the primer described in supplemental Table S1 . The viral RNA segments were synthesized with T7 RNA polymerase. The viral RNA segment (5001-6000) was not able to be amplified by unknown reason. The experiments using SARS-CoV-2 were performed in BSL3 level facilities according to approved protocols in Kumamoto University. 

We seeded 1 x 10 5 of HEK293 cells into 24-well plates in triplicate and transfected the cells with an expression vector together with p-125 Luc reporter (100 ng/well) and phRL-TK (10 ng/well, Promega) plasmids. The phRL-TK (HSV-thymidine kinase promoter) plasmid encodes Renilla luciferase and was used as an internal control. An empty plasmid was added to ensure that each transfection received the same amount of total DNA. After 24 h of transfection, luciferase assays were performed using a Dual Luciferase Assay Kit (Progemga). Luciferase activity was normalized to that of Renilla luciferase.

We seeded 1 x 10 5 of HEK293 cells into 24-well plates. Then, the cells were transfected with 100 ng of short poly I:C using Lipofectamine 2000 to determine cytokine expression after stimulation. Total RNA was isolated form the cells using TRIzol reagent (Invitrogen), according to the manufacture's protocol. cDNA was generated from the total RNA using a High-Capacity cDNA Reverse Transcription Kit (Applined Biosystems). The target mRNA was quantified with Power SYBR Green Master Mix (Applied Biosystems) using the ViiA-7 Real-Time PCR system (Applied Biosystems), and the expression levels were normalized to GAPDH.

HEK293FT cells (2 x 10 6 ) were seeded on a 10 cm dish and incubated at 37°C for 1 day.

GFP, LGP2 and LGP2 4KR ORFs were cloned into a FUIPW lentiviral vector and cotransfected with packaging plasmids into HEK293FT cells. After 3 days of transfection, the viruses were harvested and filtered (0.22 µm filter, Millipore) and used to infect HEK293 cells in the presence of polybrene (10 µg/ml). The infected cells were selected with the application of puromycine (1 µg/ml) for 3 days. Human ACE2 cDNA clone was synthesizes using HepG2 total RNA. The expression of ACE2 in HEK293 ACE2 cells was confirmed by RT-qPCR.

FLAG-tagged LGP2 and Riplet expression vectors were transfected into HEK293 cells.

After 24 h of transfection, the cell lysate was prepared, and LGP2 was purified using anti-FLAG monoclonal Abs. The isolated LGP2 was subjected to SDS-PAGE and stained with CBB.

LGP2 bands were excised from the gel. Then, the proteins in each gel slice were 

All qPCR assays and reporter gene assays were performed in triplicate (n = 3). Error bars represent SD. Statistical significance (p-value) was determined using a two-tailed Student's t-test, one-way ANOVA, or two-way ANOVA in Prism v7.0a (GraphPad --+  -----+  --------+  -------+  --------+  -----+ LGP2

LGP2 

RIG-I-like receptors: their regulation and roles in RNA sensing

Filament-like Assemblies of Intracellular Nucleic Acid Sensors: Commonalities and Differences

Double-Stranded RNA Sensors and Modulators in Innate Immunity

Immune signaling by RIG-I-like receptors

The RNA helicase RIG-I has an essential function in doublestranded RNA-induced innate antiviral responses

RIG-I-like receptors and autoimmune diseases

TRIM25 RING-finger E3 ubiquitin ligase is essential for RIG-I-mediated antiviral activity

Structural basis for ubiquitinmediated antiviral signal activation by RIG-I

NDR2 promotes the antiviral immune response via facilitating TRIM25-mediated RIG-I activation in macrophages

The Zinc-Finger Protein ZCCHC3 Binds RNA and Facilitates Viral RNA Sensing and Activation of the RIG-I-like Receptors

NLRP12 Regulates Anti-viral RIG-I Activation via Interaction with TRIM25

A distinct role of Ripletmediated K63-Linked polyubiquitination of the RIG-I repressor domain in human antiviral innate immune responses

Riplet/RNF135, a RING finger protein, ubiquitinates RIG-I to promote interferon-beta induction during the early phase of viral infection

Ubiquitin-Dependent and -Independent Roles of E3 Ligase RIPLET in Innate Immunity

REUL is a novel E3 ubiquitin ligase and stimulator of retinoic-acidinducible gene-I

Ube2D3 and Ube2N are essential for RIG-I-mediated MAVS aggregation in antiviral innate immunity

RIPLET, and not TRIM25, is required for endogenous RIG-Idependent antiviral responses

Pivotal role of RNA-binding E3 ubiquitin ligase MEX3C in 31

The ubiquitin ligase Riplet is essential for RIG-I-dependent innate immune responses to RNA virus infection

Cell type-specific involvement of RIG-I in antiviral response

ISG15-dependent Activation of the RNA Sensor MDA5 and its Antagonism by the SARS-CoV-2 papain-like protease

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Regulation of a DLK-1 and p38 MAP kinase pathway by the ubiquitin ligase RPM-1 is required for presynaptic development